Vapor,
I agree funding issues are off the table for the time being, but I would not rule out future raises before WP's anticipated commercialisation in 2025.
Despite AVR having a potential world class product, it's still a biotech junior without an income to support its progress towards profitability.
Nevertheless, AVR will remain my biggest portfolio (54%) holding, such is my faith in the product and company.
Ann: Capital Raise, page-7
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.050(0.32%) |
Mkt cap ! $300.0M | |||
| Open | High | Low | Value | Volume |
| $16.00 | $16.01 | $15.49 | $195.7K | 12.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 85 | 2 |
View Market Depth
| Last trade - 13.24pm 25/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |